Expression  ||| S:0 E:11 ||| NN
profile  ||| S:11 E:19 ||| NN
of  ||| S:19 E:22 ||| IN
IGF  ||| S:22 E:26 ||| NNP
paralog  ||| S:26 E:34 ||| NN
genes  ||| S:34 E:40 ||| NNS
in  ||| S:40 E:43 ||| IN
liver  ||| S:43 E:49 ||| NN
and  ||| S:49 E:53 ||| CC
muscle  ||| S:53 E:60 ||| NN
of  ||| S:60 E:63 ||| IN
a  ||| S:63 E:65 ||| DT
GH-transgenic  ||| S:65 E:79 ||| JJ
zebrafish  ||| S:79 E:89 ||| NNS
The  ||| S:89 E:93 ||| DT
objective  ||| S:93 E:103 ||| NN
of  ||| S:103 E:106 ||| IN
this  ||| S:106 E:111 ||| DT
study  ||| S:111 E:117 ||| NN
was  ||| S:117 E:121 ||| VBD
to  ||| S:121 E:124 ||| TO
investigate  ||| S:124 E:136 ||| VB
the  ||| S:136 E:140 ||| DT
relationship  ||| S:140 E:153 ||| NN
between  ||| S:153 E:161 ||| IN
IGFs  ||| S:161 E:166 ||| JJ
produced  ||| S:166 E:175 ||| VBN
in  ||| S:175 E:178 ||| IN
the  ||| S:178 E:182 ||| DT
liver  ||| S:182 E:188 ||| NN
and  ||| S:188 E:192 ||| CC
skeletal  ||| S:192 E:201 ||| JJ
muscle  ||| S:201 E:208 ||| NN
with  ||| S:208 E:213 ||| IN
muscle  ||| S:213 E:220 ||| NN
hypertrophy  ||| S:220 E:232 ||| VBZ
previously  ||| S:232 E:243 ||| RB
observed  ||| S:243 E:252 ||| VBN
in  ||| S:252 E:255 ||| IN
a  ||| S:255 E:257 ||| DT
line  ||| S:257 E:262 ||| NN
of  ||| S:262 E:265 ||| IN
GH-transgenic  ||| S:265 E:279 ||| JJ
zebrafish ||| S:279 E:288 ||| NN
.  ||| S:288 E:290 ||| .
In  ||| S:290 E:293 ||| IN
this  ||| S:293 E:298 ||| DT
sense ||| S:298 E:303 ||| NN
,  ||| S:303 E:305 ||| ,
we  ||| S:305 E:308 ||| PRP
evaluated  ||| S:308 E:318 ||| VBD
the  ||| S:318 E:322 ||| DT
expression  ||| S:322 E:333 ||| NN
of  ||| S:333 E:336 ||| IN
genes  ||| S:336 E:342 ||| NNS
related  ||| S:342 E:350 ||| VBN
to  ||| S:350 E:353 ||| TO
the  ||| S:353 E:357 ||| DT
IGF  ||| S:357 E:361 ||| NNP
system  ||| S:361 E:368 ||| NN
in  ||| S:368 E:371 ||| IN
liver  ||| S:371 E:377 ||| NN
and  ||| S:377 E:381 ||| CC
muscle  ||| S:381 E:388 ||| NN
of  ||| S:388 E:391 ||| IN
transgenics ||| S:391 E:402 ||| NN
,  ||| S:402 E:404 ||| ,
as  ||| S:404 E:407 ||| RB
well  ||| S:407 E:412 ||| RB
as  ||| S:412 E:415 ||| IN
the  ||| S:415 E:419 ||| DT
main  ||| S:419 E:424 ||| JJ
intracellular  ||| S:424 E:438 ||| JJ
signaling  ||| S:438 E:448 ||| NNS
pathways  ||| S:448 E:457 ||| VBP
used  ||| S:457 E:462 ||| VBN
by  ||| S:462 E:465 ||| IN
GH ||| S:465 E:467 ||| NNP
/ ||| S:467 E:468 ||| NNP
IGF  ||| S:468 E:472 ||| NNP
axis ||| S:472 E:476 ||| NN
.  ||| S:476 E:478 ||| .
Our  ||| S:478 E:482 ||| PRP$
results  ||| S:482 E:490 ||| NNS
showed  ||| S:490 E:497 ||| VBD
an  ||| S:497 E:500 ||| DT
increase  ||| S:500 E:509 ||| NN
in  ||| S:509 E:512 ||| IN
expression  ||| S:512 E:523 ||| NN
of  ||| S:523 E:526 ||| IN
igf1a ||| S:526 E:531 ||| NNP
,  ||| S:531 E:533 ||| ,
igf2a ||| S:533 E:538 ||| NNP
,  ||| S:538 E:540 ||| ,
and  ||| S:540 E:544 ||| CC
igf2b  ||| S:544 E:550 ||| CD
genes  ||| S:550 E:556 ||| NNS
in  ||| S:556 E:559 ||| IN
the  ||| S:559 E:563 ||| DT
liver ||| S:563 E:568 ||| NN
.  ||| S:568 E:570 ||| .
Moreover ||| S:570 E:578 ||| RB
,  ||| S:578 E:580 ||| ,
there  ||| S:580 E:586 ||| EX
was  ||| S:586 E:590 ||| VBD
a  ||| S:590 E:592 ||| DT
decrease  ||| S:592 E:601 ||| NN
in  ||| S:601 E:604 ||| IN
the  ||| S:604 E:608 ||| DT
expression  ||| S:608 E:619 ||| NN
of  ||| S:619 E:622 ||| IN
igf1ra  ||| S:622 E:629 ||| NNP
and  ||| S:629 E:633 ||| CC
an  ||| S:633 E:636 ||| DT
increase  ||| S:636 E:645 ||| NN
in  ||| S:645 E:648 ||| IN
muscle  ||| S:648 E:655 ||| NN
igf2r  ||| S:655 E:661 ||| NN
of  ||| S:661 E:664 ||| IN
transgenics ||| S:664 E:675 ||| NN
,  ||| S:675 E:677 ||| ,
indicating  ||| S:677 E:688 ||| VBG
a  ||| S:688 E:690 ||| DT
negative  ||| S:690 E:699 ||| JJ
response  ||| S:699 E:708 ||| NN
of  ||| S:708 E:711 ||| IN
muscle  ||| S:711 E:718 ||| NN
tissue  ||| S:718 E:725 ||| NN
with  ||| S:725 E:730 ||| IN
respect  ||| S:730 E:738 ||| NN
to  ||| S:738 E:741 ||| TO
excess  ||| S:741 E:748 ||| VB
circulating  ||| S:748 E:760 ||| VBG
IGFs ||| S:760 E:764 ||| JJ
.  ||| S:764 E:766 ||| .
Muscle  ||| S:766 E:773 ||| JJ
IGFs  ||| S:773 E:778 ||| JJ
expression  ||| S:778 E:789 ||| NN
analyses  ||| S:789 E:798 ||| NNS
revealed  ||| S:798 E:807 ||| VBD
a  ||| S:807 E:809 ||| DT
significant  ||| S:809 E:821 ||| JJ
increase  ||| S:821 E:830 ||| NN
only  ||| S:830 E:835 ||| RB
for  ||| S:835 E:839 ||| IN
igf2b ||| S:839 E:844 ||| NNP
,  ||| S:844 E:846 ||| ,
accompanied  ||| S:846 E:858 ||| VBN
by  ||| S:858 E:861 ||| IN
a  ||| S:861 E:863 ||| DT
parallel  ||| S:863 E:872 ||| JJ
induction  ||| S:872 E:882 ||| NN
of  ||| S:882 E:885 ||| IN
igfbp5a  ||| S:885 E:893 ||| CD
gene ||| S:893 E:897 ||| NN
.  ||| S:897 E:899 ||| .
The  ||| S:899 E:903 ||| DT
presence  ||| S:903 E:912 ||| NN
of  ||| S:912 E:915 ||| IN
IGFBP5a  ||| S:915 E:923 ||| NNP
may  ||| S:923 E:927 ||| MD
potentiate  ||| S:927 E:938 ||| VB
the  ||| S:938 E:942 ||| DT
IGF2  ||| S:942 E:947 ||| JJ
action  ||| S:947 E:954 ||| NN
in  ||| S:954 E:957 ||| IN
muscle  ||| S:957 E:964 ||| NN
cells  ||| S:964 E:970 ||| NNS
differentiation ||| S:970 E:985 ||| VBD
.  ||| S:985 E:987 ||| .
Regarding  ||| S:987 E:997 ||| VBG
JAK ||| S:997 E:1000 ||| NNP
/ ||| S:1000 E:1001 ||| NNP
STAT-related  ||| S:1001 E:1014 ||| JJ
genes ||| S:1014 E:1019 ||| NNS
,  ||| S:1019 E:1021 ||| ,
we  ||| S:1021 E:1024 ||| PRP
observed  ||| S:1024 E:1033 ||| VBD
an  ||| S:1033 E:1036 ||| DT
alteration  ||| S:1036 E:1047 ||| NN
in  ||| S:1047 E:1050 ||| IN
the  ||| S:1050 E:1054 ||| DT
expression  ||| S:1054 E:1065 ||| NN
profile  ||| S:1065 E:1073 ||| NN
of  ||| S:1073 E:1076 ||| IN
both  ||| S:1076 E:1081 ||| DT
stat3  ||| S:1081 E:1087 ||| NNP
and  ||| S:1087 E:1091 ||| CC
stat5a  ||| S:1091 E:1098 ||| CD
in  ||| S:1098 E:1101 ||| IN
transgenic  ||| S:1101 E:1112 ||| JJ
fish  ||| S:1112 E:1117 ||| NN
liver ||| S:1117 E:1122 ||| NN
.  ||| S:1122 E:1124 ||| .
No  ||| S:1124 E:1127 ||| DT
changes  ||| S:1127 E:1135 ||| NNS
were  ||| S:1135 E:1140 ||| VBD
observed  ||| S:1140 E:1149 ||| VBN
in  ||| S:1149 E:1152 ||| IN
the  ||| S:1152 E:1156 ||| DT
muscle ||| S:1156 E:1162 ||| NN
,  ||| S:1162 E:1164 ||| ,
suggesting  ||| S:1164 E:1175 ||| VBG
that  ||| S:1175 E:1180 ||| IN
both  ||| S:1180 E:1185 ||| DT
tissues  ||| S:1185 E:1193 ||| NNS
respond  ||| S:1193 E:1201 ||| VBP
differently  ||| S:1201 E:1213 ||| RB
to  ||| S:1213 E:1216 ||| TO
GH-transgenesis ||| S:1216 E:1231 ||| JJ
.  ||| S:1231 E:1233 ||| .
Western  ||| S:1233 E:1241 ||| JJ
blotting  ||| S:1241 E:1250 ||| JJ
analyses  ||| S:1250 E:1259 ||| NNS
indicated  ||| S:1259 E:1269 ||| VBD
an  ||| S:1269 E:1272 ||| DT
imbalance  ||| S:1272 E:1282 ||| NN
between  ||| S:1282 E:1290 ||| IN
the  ||| S:1290 E:1294 ||| DT
phosphorylation  ||| S:1294 E:1310 ||| JJ
levels  ||| S:1310 E:1317 ||| NNS
of  ||| S:1317 E:1320 ||| IN
the  ||| S:1320 E:1324 ||| DT
proliferative  ||| S:1324 E:1338 ||| NN
( ||| S:1338 E:1339 ||| -LRB-
MEK ||| S:1339 E:1342 ||| NNP
/ ||| S:1342 E:1343 ||| NNP
ERK ||| S:1343 E:1346 ||| NNP
)  ||| S:1346 E:1348 ||| -RRB-
and  ||| S:1348 E:1352 ||| CC
hypertrophic  ||| S:1352 E:1365 ||| NNS
( ||| S:1365 E:1366 ||| -LRB-
PI3K ||| S:1366 E:1370 ||| NNP
/ ||| S:1370 E:1371 ||| NNP
Akt ||| S:1371 E:1374 ||| NNP
)  ||| S:1374 E:1376 ||| -RRB-
pathways ||| S:1376 E:1384 ||| NN
,  ||| S:1384 E:1386 ||| ,
in  ||| S:1386 E:1389 ||| IN
favor  ||| S:1389 E:1395 ||| NN
of  ||| S:1395 E:1398 ||| IN
the  ||| S:1398 E:1402 ||| DT
latter ||| S:1402 E:1408 ||| NN
.  ||| S:1408 E:1410 ||| .
In  ||| S:1410 E:1413 ||| IN
summary ||| S:1413 E:1420 ||| NN
,  ||| S:1420 E:1422 ||| ,
the  ||| S:1422 E:1426 ||| DT
results  ||| S:1426 E:1434 ||| NNS
of  ||| S:1434 E:1437 ||| IN
this  ||| S:1437 E:1442 ||| DT
study  ||| S:1442 E:1448 ||| NN
suggest  ||| S:1448 E:1456 ||| VBP
that  ||| S:1456 E:1461 ||| IN
the  ||| S:1461 E:1465 ||| DT
hypertrophy  ||| S:1465 E:1477 ||| NN
caused  ||| S:1477 E:1484 ||| VBN
by  ||| S:1484 E:1487 ||| IN
GH-transgenesis  ||| S:1487 E:1503 ||| JJ
in  ||| S:1503 E:1506 ||| IN
zebrafish  ||| S:1506 E:1516 ||| NNS
may  ||| S:1516 E:1520 ||| MD
be  ||| S:1520 E:1523 ||| VB
due  ||| S:1523 E:1527 ||| JJ
to  ||| S:1527 E:1530 ||| TO
circulating  ||| S:1530 E:1542 ||| VB
IGFs  ||| S:1542 E:1547 ||| JJ
produced  ||| S:1547 E:1556 ||| VBN
by  ||| S:1556 E:1559 ||| IN
the  ||| S:1559 E:1563 ||| DT
liver ||| S:1563 E:1568 ||| NN
,  ||| S:1568 E:1570 ||| ,
with  ||| S:1570 E:1575 ||| IN
an  ||| S:1575 E:1578 ||| DT
important  ||| S:1578 E:1588 ||| JJ
participation  ||| S:1588 E:1602 ||| NN
of  ||| S:1602 E:1605 ||| IN
muscle  ||| S:1605 E:1612 ||| NN
IGF2b ||| S:1612 E:1617 ||| NN
.  ||| S:1617 E:1619 ||| .
This  ||| S:1619 E:1624 ||| DT
group  ||| S:1624 E:1630 ||| NN
of  ||| S:1630 E:1633 ||| IN
IGFs  ||| S:1633 E:1638 ||| NNP
appears  ||| S:1638 E:1646 ||| VBZ
to  ||| S:1646 E:1649 ||| TO
be  ||| S:1649 E:1652 ||| VB
favoring  ||| S:1652 E:1661 ||| VBG
the  ||| S:1661 E:1665 ||| DT
hypertrophic  ||| S:1665 E:1678 ||| JJ
intracellular  ||| S:1678 E:1692 ||| JJ
pathway  ||| S:1692 E:1700 ||| NN
in  ||| S:1700 E:1703 ||| IN
muscle  ||| S:1703 E:1710 ||| NN
tissue  ||| S:1710 E:1717 ||| NN
of  ||| S:1717 E:1720 ||| IN
transgenic  ||| S:1720 E:1731 ||| JJ
zebrafish ||| S:1731 E:1740 ||| NN
.  ||| S:1740 E:1742 ||| .
